- Conditions
- Gastroesophageal Reflux Disease (GERD)
- Interventions
- Dexlansoprazole
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 2 Years to 11 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 6
- States / cities
- Mobile, Alabama • San Francisco, California • Atlanta, Georgia + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–16
of 16
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Erosive Esophagitis
- Interventions
- Nexium 20mg, Nexium 10mg
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 1 Year to 11 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 11
- States / cities
- Mobile, Alabama • Sacramento, California • Miami, Florida + 7 more
- Conditions
- Pediatric Gastroesophageal Reflux Disease
- Interventions
- Dexlansoprazole
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 1 Month to 11 Months
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Louisville, Kentucky • Baltimore, Maryland + 3 more
- Conditions
- Eosinophilic Esophagitis
- Interventions
- Intubated with Sevoflurane (IS), Intubated with Propofol (IP), Zofran - no intubation, Propofol
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 1 Year to 12 Years
- Enrollment
- 179 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Clostridium Difficile Infection
- Interventions
- Omeprazole (suspension), Lifestyle Modification
- Drug · Other
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 0 Years to 4 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Pediatric Obesity, NAFLD, GERD
- Interventions
- Lansoprazole, Pantoprazole, Midazolam
- Drug
- Lead sponsor
- Children's Mercy Hospital Kansas City
- Other
- Eligibility
- 6 Years to 21 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Gastroesophageal Reflux
- Interventions
- Rabeprazole sodium 5 mg, Rabeprazole sodium 10 mg, Placebo
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 1 Month to 11 Months
- Enrollment
- 344 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Columbiana, Alabama • Dothan, Alabama + 40 more
- Conditions
- Obesity, GERD
- Interventions
- Pantoprazole
- Drug
- Lead sponsor
- Children's Mercy Hospital Kansas City
- Other
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Gastroesophageal Reflux Disease (GERD), Erosive Esophagitis, Non-erosive Esophagitis
- Interventions
- Esomeprazole (Nexium)
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 1 Year to 11 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 24
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Wilmington, Delaware + 21 more
- Conditions
- Gastroesophageal Reflux Disease (GERD)
- Interventions
- Rabeprazole sodium 5 mg, Rabeprazole sodium 10 mg
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 1 Month to 11 Months
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 13
- States / cities
- Little Rock, Arkansas • Oakland, California • Washington D.C., District of Columbia + 10 more
- Conditions
- Gastroesophageal Reflux
- Interventions
- Dexlansoprazole
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 1 Year to 11 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 4
- States / cities
- Anaheim, California • Miami Garden, Florida • Kansas City, Missouri + 1 more
- Conditions
- Voice Disorders, Gastroesophageal Reflux
- Interventions
- Neuromuscular Electrical Stimulation, Unstimulated
- Behavioral
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 6 Years to 11 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Gastroesophageal Reflux Disease (GERD)
- Interventions
- Esomeprazole (Nexium)
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 28
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Wilmington, Delaware + 25 more
- Conditions
- Gastroesophageal Reflux Disease
- Interventions
- IV pantoprazole
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 1 Year to 16 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 3
- States / cities
- Dallas, Texas • Salt Lake City, Utah
- Conditions
- Gastroesophageal Reflux
- Interventions
- rabeprazole sodium
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Gastroesophageal Reflux Disease (GERD), Eosinophilic Esophagitis (EoE), Functional Dyspepsia
- Interventions
- Standard of Care esophagogastroduodenoscopy (EGD) with measurement of mucosal impedance
- Diagnostic Test
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 127 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee